Hypoglycemia in Dogs (Canis) | Vetlexicon
canis - Articles

Hypoglycemia

ISSN 2398-2942

Contributor(s) :


Introduction

  • Plasma glucose less than 3.0 mmol/L (55 mg/dL) is significant.
  • In animals which have chronically low blood glucose, concentrations may have to drop very low (less than 2.0 mmol/L (35 mg/dL) before clinical signs are exhibited.
  • Signs: ataxia, weakness, disorientation, seizures.
  • Diagnosis: blood or plasma glucose concentrations. 
  • Treatment: feeding and/or glucose (oral or intravenous) and correct underlying cause.

Presenting signs

  • Weakness/collapse.
  • Ataxia/incoordination.
  • Lethargy/sleepiness.
  • Trembling/muscle tremors.
  • Anxiety/behavioral changes/bed wetting.
  • Disorientation/confusion/apparent blindness.
  • Collapse with or without loss of consciousness.
  • Seizures.
  • Other neurological signs.
  • Polyphagia.

Acute presentation

  • Often present following collapse or seizure.
  • Signs may be acute or intermittent/episodic.
  • Diabetic dogs receiving insulin treatment.

Age predisposition

  • Older dogs (neoplastic causes).
  • Neonate (malnourishment/hypothermia).

Breed/Species predisposition

  • Toy and miniature breeds - prone to hypoglycemia if inadequate feeding and hypothermia when neonates.
  • Large breeds overrepresented with insulinomas Pancreas: neoplasia: insulinoma.
  • Working dogs during hard work.

Special risks

Pathogenesis

Etiology

Predisposing factors

  • Neonatal/juvenile animals have immature mechanisms for regulating blood glucose.
  • Over-activity, cold, other stresses tend to reduce blood glucose.
  • Insulin treatment of diabetic dogs.
  • Hard work - appears as functional disorder.

Pathophysiology

  • Decrease of blood glucose towards the lower end of the physiological range stimulates secretion of counter-regulatory hormones (glucagon, adrenaline, noradrenaline, cortisol, and growth hormone), which increase glycogenolysis and gluconeogenesis and so increase blood glucose concentration.
  • Hypoglycemia results from failure of these mechanisms due to excess insulin, deficiency of counter-regulatory hormones, and/or inadequate glucose production.
  • Hypoglycemia also → and increased appetitie (might even result in pica Pica).
  • If these protective counter-regulatory mechanisms are overwhelmed, hypoglycemia → reduced glucose availability to central and peripheral nervous system → lethargy, weakness, ataxia, disorientation, seizures.
  • Prolonged, severe hypoglycemia → reversible or irreversible brain damage, and rarely → death.

Specific

  • Neonatal hypoglycemia - gluconeogenesis limited in neonate and limited glycogen stores rapidly deplete - relies upon regular feeding - may develop hypoglycemia after only 12 hour fast.
  • Starvaion - severe malnutrition → decreased hepatic glycogen, decreased fat stores → decreased gluconeogenesis → hypoglycemia.
  • Glycogen storage diseases Storage disease - genetic abnormality → deficiency in enzymes/defective enzymes involved in glycogen degradation → hypoglycemia. 
  • Exogenous agents: direct drug action → hypoglycemia.
  • Bacterial shock → depletion of glycogen stores, increased peripheral use of glucose, decreased gluconeogenesis + ?circulatory factors → hypoglycemia.
  • Extra-pancreatic tumors:
    • Secretion of insulin/insulin-like/insulin precursor.
    • Accelerated glucose utilization.
    • Inhibited glucose release from liver → hypoglycemia.
  • Functional islet cell tumor  → insulin secretion → hypoglycemia.
  • Insulin overdose, inappetence/starvation, concurrent illness and/or sudden increase in exercise/stress levels during treatment with insulin may → hypoglycemia.

Diagnosis

Subscribe To View

This article is available to subscribers.

Try a free trial today or contact us for more information.

Treatment

Subscribe To View

This article is available to subscribers.

Try a free trial today or contact us for more information.

Prevention

Subscribe To View

This article is available to subscribers.

Try a free trial today or contact us for more information.

Outcomes

Subscribe To View

This article is available to subscribers.

Try a free trial today or contact us for more information.

Further Reading

Publications

Refereed papers

  • Recent references from PubMed and VetMedResource.
  • Behrend E, Holford A, Lathan P, Rudinsky R et al (2018) 2018 AAHA Diabetes Management Guidelines for Dogs and Cats. JAAHA 54 (1), 1-21 PubMed.
  • Brooks E D, Yi H, Austin S L et al (2016) Natural progression of canine glycogen storage disease type IIIa. Comp Med 66 (1), 41-51 PubMed.
  • Münnich A, Küchenmeister U (2014) Causes, diagnosis and therapy of common diseases in neonatal puppies in the first days of life: cornerstones of practical approach. Reprod Domest Anim 49 (Suppl 2), 64-74 PubMed.
  • Northrup N C, Rasnick K M, Gieger T L, Kosarek C E et al (2013) Prospective evaluation of biweekly streptozotocin in 19 dogs with insulinoma. J Vet Intern Med 27 (3), 483-490 PubMed.
  • Goutal C M, Brugmann B L, Ryan K A (2012) Insulinoma in dogs: a review. JAAHA 48 (3), 151-163 PubMed.
  • Piscitelli C M, Dunayer E K, Aumann M (2010) Xytitol toxicity in dogs. Compen Contin Educ Vet 32 (2), E1-4 PubMed.
  • Zini E, Glaus T M, Minuto F et al (2007) Paraneoplastic hypoglycemia due to an insulin-like growth factor type-II secreting hepatocellular carcinoma in a dog. J Vet Intern Med 21 (1), 193-195 PubMed.
  • Syme H M & Scott-Moncrieff (1998) Chronic hypoglycaemia in a hunting dog due to secondary hypoadrenocorticism. JSAP 39 (7), 348-351 PubMed.
  • Bagley R S, Levy J K & Malarkey D E (1996) Hypoglycaemia associated with intrabdominal leiomyoma and leiomyosarcoma in six dogs. JAVMA 208 (1), 69-71 PubMed.
  • Leifer C E, Peterson M E & Matus R E (1986) Insulin secreting tumours - diagnosis and medical and surgical management in 55 dogs. JAVMA 188 (1), 60-64 PubMed.
  • Leifer C E, Peterson M E, Matus R E & Patnaik A K (1985) Hypoglycaemia associated with nonislet cell tumours in 13 dogs. JAVMA 186 (1), 53-55 PubMed.